9 Meters Biopharma (NMTR) Provides Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
February 28, 2022 4:16 PM ESTRALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide (GLP-1) agonist in a Phase 2 trial for adults with short bowel syndrome (SBS), and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease.
The vurolenatide Phase 2 trial known as the VIBRANT (VurolenatIde for short Bowel syndrome Regardless of... More
